Down-regulated KLF17 expression is associated with tumor invasion and poor prognosis in hepatocellular carcinoma

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Liu, Fu Yao ^a   Deng, Yue Ling ^a   Li, Yuan ^a   Zeng, Dan ^a   Zhou, Zhen Zhen ^a   Tian, De An ^a   Liu, Mei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

EMT; Invasion; KLF17; Primary hepatocellular carcinoma; Prognosis

Indexed keywords

KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 17; PROTEIN ZO1; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; KLF17 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL MIGRATION; CELL STRAIN HEPG2; COHORT ANALYSIS; DISEASE SEVERITY; DOWN REGULATION; EMBRYO; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SURVIVAL TIME; TUMOR GENE; TUMOR INVASION; TUMOR THROMBUS; TUMOR VOLUME; WESTERN BLOTTING; BIOSYNTHESIS; CANCER STAGING; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DOWN-REGULATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84880597266     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0425-3     Document Type: Article

References (26)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674-87.
2. Liotta LA. Mechanisms of cancer invasion and metastasis. Important advances in oncology. 1985:28-41. (Epub 1985/01/01).
3. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871-90.
4. Suske G, Bruford E, Philipsen S. Mammalian SP/KLF transcription factors: bring in the family. Genomics. 2005;85(5):551-6.
5. van Vliet J, Crofts LA, Quinlan KG, Czolij R, Perkins AC, Crossley M. Human KLF17 is a new member of the Sp/KLF family of transcription factors. Genomics. 2006;87(4):474-82.
6. Kim J, Shin S, Subramaniam M, Bruinsma E, Kim TD, Hawse JR, et al. Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10. Biochem Biophys Res Commun. 2010;401(3):412-6.
7. Spittau G, Happel N, Behrendt M, Chao TI, Krieglstein K, Spittau B. Tieg1/Klf10 is upregulated by NGF and attenuates cell cycle progression in the pheochromocytoma cell line PC12. J Neurosci Res. 2010;88(9):2017-25.
8. Kaczynski J, Cook T, Urrutia R. Sp1- and Kruppel-like transcription factors. Genome Biol. 2003;4(2):206.
9. Humbert M, Halter V, Shan D, Laedrach J, Leibundgut EO, Baerlocher GM, et al. Deregulated expression of Kruppel-like factors in acute myeloid leukemia. Leukemia Res. 2011;35(7):909-13.
10. McConnell BB, Yang VW. Mammalian Kruppel-like factors in health and diseases. Physiol Rev. 2010;90(4):1337-81.
11. Antin PB, Pier M, Sesepasara T, Yatskievych TA, Darnell DK. Embryonic expression of the chicken Kruppel-like (KLF) transcription factor gene family. Dev Dyn. 2010;239(6):1879-87.
12. X-d Cai, Y-b Zhou, L-x Huang, Q-l Zeng, L-j Zhang, Q-q Wang, et al. Reduced expression of Krüppel-like factor 17 is related to tumor growth and poor prognosis in lung adenocarcinoma. Biochem Biophys Res Comm. 2012;418(1):67-73.
13. Gumireddy K, Li A, Gimotty PA, Klein-Szanto AJ, Showe LC, Katsaros D, et al. KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol. 2009;11(11):1297-304.
14. Fernandez-Zapico ME, Lomberk GA, Tsuji S, DeMars CJ, Bardsley MR, Lin YH, et al. A functional family-wide screening of SP/KLF proteins identifies a subset of suppressors of KRAS-mediated cell growth. Biochem J. 2011;435(2):529-37.
15. Vetter D, Cohen-Naftaly M, Villaneuva A, Lee YA, Kocabayoglu P, Hannivoort R, et al. Enhanced hepatocarcinogenesis in mouse models and human HCC by coordinate KLF6 depletion and increased mRNA splicing. Hepatology. 2012. (Epub 2012/04/27).
16. Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, et al. Carcinogen-induced hepatic tumors in KLF6 ± mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. Hepatology. 2011;54(2):522-31.
17. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704-15.
18. Sleeman JP, Thiery JP. SnapShot: the epithelial-mesenchymal transition. Cell. 2011;145(1):162.
19. Ishiyama N, Lee SH, Liu S, Li GY, Smith MJ, Reichardt LF, et al. Dynamic and static interactions between p120 catenin and E-cadherin regulate the stability of cell-cell adhesion. Cell. 2010;141(1):117-28.
20. Patel SD, Ciatto C, Chen CP, Bahna F, Rajebhosale M, Arkus N, et al. Type II cadherin ectodomain structures: implications for classical cadherin specificity. Cell. 2006;124(6):1255-68.
21. Philippova M, Joshi MB, Kyriakakis E, Pfaff D, Erne P, Resink TJ. A guide and guard: the many faces of T-cadherin. Cell Signal. 2009;21(7):1035-44.
22. Chan DW, Lee JMF, Chan PCY, Ng IOL. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells. Int J Cancer. 2008;123(5):1043-52.
23. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68(18):3033-46.
24. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol. 2010;21(Suppl 7):789-92.
25. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celia-Terrassa T, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med. 2011;17(9):1101-8.
26. Ellenrieder V. TGFβ-regulated gene expression by smads and Sp1/KLF-like transcription factors in cancer. Anti cancer Res. 2008;28(3):1531-9.